Pathogenesis and management of dialysis-related amyloid bone disease

American Journal of the Medical Sciences

Volumn 317, Issue 6, 1999, Pages 410-415

  Nangaku, Masaomi ^a   Miyata, Toshio ^a   Kurokawa, Kiyoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Dialysisamyloidosis; Renal osteodystrophy; Uremia; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN;

AMYLOIDOSIS; BIOCOMPATIBILITY; BONE DISEASE; BONE EROSION; BONE PLATE; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSIS; DIALYSIS MEMBRANE; GLYCATION; HUMAN; OXIDATIVE STRESS; RENAL OSTEODYSTROPHY; TISSUE INJURY; UREMIA;

EID: 0033506535     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9629(15)40555-5     Document Type: Conference Paper

References (61)

1. Farrell J, Bastani B. β2-microglobulin amyloidosis in chronic dialysis patients: a case report and review of the literature. J Am Soc Nephrol 1997;8:509-14.
2. Floege J, Schaeffer J, Koch KM, et al. Dialysis related amyloidosis: a disease of chronic retention and inflammation? Kidney Int 1992;38(Suppl):S78-85.
3. Floege J, Ehlerding G. Beta-2-microglobulin-associated amyloidosis. Nephron 1996;72:9-26.
4. Miyata T, Jadoul M, Kurokawa K, et al. β2-Microglobulin in renal disease. J Am Soc Nephrol 1998;9:1723-35.
5. Koch K. Dialysis-related amyloidosis. Kidney Int 1992;41: 1416-29.
6. Gejyo F, Homma N, Arakawa M. Carpal tunnel syndrome and beta-2-microglobulin-related amyloidosis in chronic hemodialysis patients. Blood Purif 1988;6:125-31.
7. Charra B, Calemard E, Laurent G. Chronic renal failure treatment duration and mode: Their relevance to the late dialysis periarticular syndrome. Blood Purif 1988;6:117-24.
8. van Ypersele de Strihou C, Jadoul M, Malghem J, et al. Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis. The Working Party on Dialysis Amyloidosis. Kidney Int 1991;39:1012-9.
9. Schwartz A, Keller F, Seyfert S, et al. Carpal tunnel syndrome: a major complication in long-term hemodialysis patients. Clin Nephrol 1984;22:133-7.
10. Matsuo K, Nakamoto M, Yasunaga C, et al. Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients. Kidney Int 1997;52:832-8.
11. Floege J, Brandis A, Nonnast-Daniel B, et al. Subcutaneous amyloid tumor of beta-2-microglobulin origin in a long-term hemodialysis patient. Nephron 1989;53:73-5.
12. Campistol JM, Sole M, Munoz GJ, et al. Systemic involvement of dialysis-amyloidosis. Am J Nephrol 1990;10:389-96.
13. Ohashi K, Hara M, Kawai R, et al. Cervical discs are most susceptible to β2-microglobulin amyloid deposition in the vertebral column. Kidney Int 1992;41:1646-52.
14. Gejyo F, Yamada T, Odani S, et al. A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin. Biochem Biophys Res Commun 1985; 129:701-6.
15. Jadoul M, Garbar C, Noel H, et al. Histological prevalence of β2-microglobulin amyloidosis in haemodialysis: a prospective post-mortem study. Kidney Int 1997;51:1928-32.
16. Argiles A, Mourad G, Kerr PG, et al. Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. Nephrol Dial Transplant 1994;9:662-7.
17. Gejyo F, Homma N, Suzuki Y, et al. Serum levels of beta-2-microglobulin as a new form of amyloid protein in patients undergoing long-term hemodialysis. N Engl J Med 1986;314:585-6.
18. Bommer J, Seelig P, Seelig R, et al. Determinants of plasma beta-2-microglobulin concentration: Possible relation to membrane biocompatibility. Nephrol Dial Transplant 1987;2:22-25.
19. Argiles A, Derancourt J, Jauregui-Adell J, et al. Biochemical characterization of serum and urinary β2 microglobulin in end-stage renal disease patients. Nephrol Dial Transplant 1992;7:1106-10.
20. Ogawa H, Saito A, Oda O, et al. Detection of novel β2-microglobulin in the serum of hemodialysis patients and its amyloidogenic predisposition. Clin Nephrol 1988;30:158-63.
21. Miyata T, Taneda S, Kawai R, et al. Identification of pentosidine as a native structure for advanced glycation end products in β2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996;93:2353-8.
22. Miyata T, Oda O, Inagi R, et al. β2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993; 92:1243-52.
23. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
24. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science 1978;200: 21-7.
25. McCance DR, Dyer DG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470-8.
26. Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation m skin correlates with severity of complication in individuals with long standing IDDM. Diabetes 1992;41:1286-92.
27. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993;91:2463-9.
28. Miyata T, Hori O, Zhang JH, et al. The receptor for advanced glycation end products mediates the interaction of AGE-β2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: implication for the pathogenesis of dialysis-related amyloidosis. J Clin Invest 1996;98:1088-94.
29. Kirstein M, Brett J, Badoff S, et al. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease and aging. Proc Natl Acad Sci U S A 1990;87:9010-4.
30. Kume S, Takeya M, Mori T, et al. Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J Pathol 1995;147:654-67.
31. Vlassara H, Brownlee M, Manogue KR, et al. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-8.
32. Miyata T, Ueda Y, Shinzato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7: 1198-206.
33. Miyata T, Ueda Y, Yoshida A, et al. Clearance of pentosidine an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-7.
34. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 1991;325:836-42.
35. ∈-(carboxymethyl)lysine is increased in uremia. Kidney Int 1997; 52:1064-7.
36. Miyata T, Fu MX, Kurokawa K, et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? Kidney Int 1998 Oct;54(4):1290-5.
37. Glomb MA, Monnier VM. Mechanism of protein modification by glyoxal and glycoaldehyde, reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-26.
38. Baynes JW. Perspectives in diabetes: role of oxidative stress m development of complications in diabetes. Diabetes 1991; 40:405-12.
39. Wells-Knecht KJ, Zyzak DV, Litchfield JE, et al. Mechanism of autoxidative glycosylation: Identification of glyoxal and arabinose as intermediates in the autoxidative modification of protein by glucose. Biochemistry 1995;34:3702-9.
40. Wells-Knecht MA, Thorpe SR, Baynes JW. Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995;34:15134-41.
41. Miyata T, Maeda K, Kurokawa K, et al. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997; 12:255-8.
42. Dyer DG, Blackledge JA, Thorpe SR, et al. Formation of pentosidine during nonenzymatic browning of protein by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266:11654-60.
43. ∈-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 1990;29:10964-70.
44. Miyata T, Wada Y, Cai Z, et al. Implication of an increased oxidative stress in the formation of advanced glycation end products in patients with end-stage renal failure. Kidney Int 1997;51:1170-81.
45. Canestrari F, Galli F, Giorgini A, et al. Erythrocyte redox state in uremic anemia: effects of hemodialysis and relevance of glutathione metabolism. Acta Haematol 1994;91:187-93.
46. Kumano K, Yokota S, Go M, et al. Quantitative and qualitative changes of serum albumin in CAPD patients. Adv Perit Dial 1992;8:127-30.
47. Yeung J. Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat. Methods Find Exp Clin Pharmacol 1991;13:23-28.
48. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-13.
49. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
50. Miyata T, van Ypersele de Strihou C, Kurokawa K, et al. Alterations in non-enzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999;55:389-99.
51. Miyata T, Ueda Y, Yasuda Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: Carbonyl stress in uremia. J Am Soc Nephrol 1998;9:2349-56.
52. Miyata T, Iida Y, Ueda Y, et al. Monocyte/macrophage response to β2-microglobulin modified with the advanced glycation end products. Kidney Int 1996;49:538-50.
53. Miyata T, Inagi R, Iida Y, et al. Involvement of β2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis: induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-α and interleukin-1. J Clin Invest 1994;93:521-8.
54. Iida Y, Miyata T, Inagi R, et al. β2-Microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Biochem Biophys Res Commun 1994;201:1235-41.
55. Miyata T, Notoya K, Yoshida K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 1997;8:260-70.
56. Jadoul M, Malghem J, vande Berg B, et al. Ultrasonography of joint capsules and tendons in dialysis-related amyloidosis. Kidney Int 1993;41:S106-10.
57. Floege J. Beta-2-microglobulin derived amyloid and acquired cystic kidney disease. In: (Johnson RJ, Feehally J, editors). Principles of nephrology. London: Mosby International; in press.
58. Jadoul M, Drucke T, Zingraff J, et al. Does dialysis-related amyloidosis regress after transplantation ? Nephrol Dial Transplant 1997;12:655-7.
59. Miura Y, Ishiyama T, Inomata A, et al. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis. Nephron 1992;60:268-73.
60. Kuchle D, Fricke H, Held E, et al. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis. Am J Nephrol 1996;16:484-8.
61. Chanard J, Bindi P, Lauvaud S, et al. Carpal tunnel syndrome and type o dialysis membrane. Br Med J 1989;298: 867-8.